GSK 2838232

Drug Profile

GSK 2838232

Alternative Names: GSK2838232

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antivirals
  • Mechanism of Action HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 05 May 2017 GlaxoSmithKline terminates a phase I trial in HIV infections treatment (In volunteers) in USA (NCT02289495) prior to May 2017
  • 13 Mar 2017 Phase-II clinical trials in HIV infections treatment (Treatment-naive, Monotherapy) in USA (PO, Capsule)
  • 12 Jan 2017 GlaxoSmithKline plans a phase II trial for HIV infections treatment (Treatment-naive, Monotherapy) (PO) in USA (NCT03045861)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top